Stoke Therapeutics Inc (NASDAQ:STOK) price on Wednesday, February 05, rose 0.79% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $12.70.
A look at the stock’s price movement, the close in the last trading session was $12.60, moving within a range at $12.5 and $12.98. The beta value (5-Year monthly) was 0.948. Turning to its 52-week performance, $17.58 and $4.09 were the 52-week high and 52-week low respectively. Overall, STOK moved 10.53% over the past month.
Stoke Therapeutics Inc’s market cap currently stands at around $672.68 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 4.2M for the company’s revenue for the quarter, with a low and high estimate of 3.5M and 5M respectively. The average forecast suggests up to a 49.89% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 17.41M, representing a 98.32% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that STOK is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 4 recommend STOK as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
STOK’s current price about 24.26% and 13.30% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 67.55, while 7-day volatility ratio is 7.57% and 7.86% in the 30-day chart. Further, Stoke Therapeutics Inc (STOK) has a beta value of 0.92, and an average true range (ATR) of 0.78. Analysts have given the company’s stock an average 52-week price target of $26.5, forecast between a low of $18 and high of $35. Looking at the price targets, the low is -41.73% off current price level while to achieve the yearly target high, price needs to move -175.59%. Nonetheless, investors will most likely welcome a -108.66% jump to $26.5 which is the analysts’ median price.
If we refocus on Stoke Therapeutics Inc (NASDAQ:STOK), historical trading data shows that trading volumes averaged 0.71 over the past 10 days and 720.22K over the past 3 months. The company’s latest data on shares outstanding shows there are 52.94 million shares.
The 18.69% of Stoke Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 90.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.75 million on 2025-01-15, giving us a short ratio of 9.5. The data shows that as of 2025-01-15 short interest in Stoke Therapeutics Inc (STOK) stood at 2467.0 of shares outstanding, with shares short rising to 7.26 million registered in 2024-12-13. Current price change has pushed the stock 15.14% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the STOK stock continues to rise going into the next quarter.
